文献速递消化系统肿瘤

吉西他滨-厄洛替尼对比吉西他滨-厄洛替尼-卡培他滨一线治疗转移性胰腺癌患者:西班牙TTD协作组IIb期随机研究的疗效与安全性结果

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
PubMed 文献 · Eur J Cancer · 2017-03-07

这项IIb期随机研究纳入120例初治转移性胰腺癌患者,随机接受吉西他滨+厄洛替尼+卡培他滨(GEC)或吉西他滨+厄洛替尼(GE)治疗。GEC组与GE组中位无进展生存期分别为4.3个月和3.8个月(HR 0.88,95%CI 0.58-1.31;p=0.52),无显著差异;中位总生存期分别为6.8个月和7.7个月(HR 1.09,95%CI 0.72-1.63;p=0.69)。皮疹(≥1级)患者较无皮疹(0级)患者PFS和OS显著更长。

要点

  • GEC与GE一线治疗转移性胰腺癌的PFS无显著差异(HR 0.88,95%CI 0.58-1.31;p=0.52)。
  • GEC组3/4级中性粒细胞减少(43% vs 15%;p=0.0008)和黏膜炎(9% vs 0%;p=0.03)显著高于GE组。
  • 皮疹(≥1级)患者较无皮疹(0级)患者PFS(5.5 vs 2.0个月;HR 0.39)和OS(9.5 vs 4.0个月;HR 0.51)显著更长。

核心结论

  • 在转移性胰腺癌患者中,GEC方案的PFS与GE方案无显著差异。
  • 皮疹强烈预测厄洛替尼疗效。

研究设计与样本

  • 西班牙TTD协作组开展的IIb期随机研究,纳入120例既往未治疗的转移性胰腺癌患者。
  • 患者随机接受G(1000 mg/m2,第1、8、15天)+E(100 mg/天,第1-28天)+C(1660 mg/m2,第1-21天)或GE方案,每4周重复,直至进展或不可耐受毒性。
  • 主要终点为无进展生存期(PFS);次要终点为总生存期(OS)、缓解率、皮疹与PFS/OS的关系及安全性。
  • 中位年龄63岁,ECOG体力状态0/1/2分别为33%/58%/8%;中位随访16.5个月。

主要发现

  • GEC组与GE组中位PFS分别为4.3个月和3.8个月(HR 0.88,95%CI 0.58-1.31;p=0.52)。
  • GEC组与GE组中位OS分别为6.8个月和7.7个月(HR 1.09,95%CI 0.72-1.63;p=0.69)。
  • 3/4级中性粒细胞减少GEC组43% vs GE组15%(p=0.0008);3/4级黏膜炎GEC组9% vs GE组0%(p=0.03),为仅有的显著差异。
  • 皮疹(≥1级)患者较无皮疹(0级)患者PFS为5.5 vs 2.0个月(HR 0.39,95%CI 0.26-0.6;p<0.0001)。
  • 皮疹(≥1级)患者较无皮疹(0级)患者OS为9.5 vs 4.0个月(HR 0.51,95%CI 0.33-0.77;p=0.0014)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gemcitabine and erlotinib have shown a survival benefit in the first-line setting in metastatic pancreatic cancer (mPC). The aim of this study was to assess whether combining capecitabine (C) with gemcitabine + erlotinib (GE) was safe and effective versus GE in patients with mPC. PATIENTS AND METHODS: Previously untreated mPC patients were randomised to receive G (1000 mg/m2, days 1, 8, 15) + E (100 mg/day, days 1-28) + C (1660 mg/m2, days 1-21) or GE, q4 weeks, until progression or unacceptable toxicity. Primary end-point: progression-free survival (PFS); secondary end-points: overall survival (OS), response rate, relationship of rash with PFS/OS and safety. RESULTS: 120 patients were randomised, median age 63 years, ECOG status 0/1/2 33%/58%/8%; median follow-up 16.5 months. Median PFS in the gemcitabine-erlotinib-capecitabine (GEC) and GE arms was 4.3 and 3.8 months, respectively (hazard ratio [HR]: 0.88, 95% confidence interval [CI]: 0.58-1.31; p = 0.52). Median OS in the GEC and GE arms was 6.8 and 7.7 months, respectively (HR: 1.09, 95% CI: 0.72-1.63; p = 0.69). Grade 3/4 neutropenia (GEC 43% versus GE 15%; p = 0.0008) and mucositis (GEC 9% versus GE 0%; p = 0.03) were the only statistically significant differences in grade 3/4 adverse events. PFS and OS were significantly longer in patients with rash (grade ≥1) versus no rash (grade = 0): PFS 5.5 versus 2.0 months (HR = 0.39, 95% CI: 0.26-0.6; p < 0.0001) and OS: 9.5 versus 4.0 months (HR = 0.51, 95% CI: 0.33-0.77; p = 0.0014). CONCLUSION: PFS with GEC was not significantly different to that with GE in patients with mPC. Skin rash strongly predicted erlotinib efficacy. The study was registered with ClinicalTrials.gov: NCT01303029.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Irigoyen A, Gallego J, Guillén Ponce C, et al. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. Eur J Cancer. 2017. PMID: 28222309. doi:10.1016/j.ejca.2016.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。